Shares of Inovio Pharmaceuticals Inc. INO advanced 1.90% to $1.61 Friday, on what proved to be an all-around positive trading ...

Inovio Pharmaceuticals (INO) has been beaten down lately with too much selling pressure. While the stock has lost 11.4% over ...

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. INOVIO (NASDAQ ...

Investors might want to bet on Inovio Pharmaceuticals (INO), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Inovio Pharmaceuticals Inc. closed 89.14% below its 52-week high of $13.44, which the company reached on May 16th.

Inovio Pharmaceuticals, Inc.’s INO share price has surged by 10.67%, which has investors questioning if this is right time to sell.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

INO stock opened at $1.92 on Friday. Inovio Pharmaceuticals has a 52 week low of $1.74 and a 52 week high of $14.75. The firm’s fifty day moving average is $2.04 and its 200 day moving average ...

Desjardins analyst A. Leon anticipates that the company will earn $0.01 per share for the quarter. Desjardins also issued ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...